Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday. They presently have a $7.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 4.95% from the stock’s previous close.

A number of other research analysts have also issued reports on ZYNE. Oppenheimer Holdings, Inc. set a $8.00 price objective on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. BidaskClub upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Maxim Group set a $32.00 price objective on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $35.00 price objective on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, May 13th. Finally, Jefferies Group LLC restated a “buy” rating and set a $32.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $20.00.

Shares of Zynerba Pharmaceuticals (ZYNE) opened at 6.67 on Tuesday. The stock’s 50 day moving average price is $17.81 and its 200 day moving average price is $19.61. Zynerba Pharmaceuticals has a 1-year low of $5.93 and a 1-year high of $25.95. The stock’s market cap is $88.42 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.04. On average, equities research analysts anticipate that Zynerba Pharmaceuticals will post ($2.46) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by HC Wainwright to “Neutral”” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/08/zynerba-pharmaceuticals-inc-zyne-downgraded-by-hc-wainwright-to-neutral.html.

In other Zynerba Pharmaceuticals news, CFO James E. Fickenscher bought 5,200 shares of the business’s stock in a transaction on Friday, May 12th. The shares were purchased at an average price of $19.82 per share, with a total value of $103,064.00. Following the purchase, the chief financial officer now directly owns 12,200 shares of the company’s stock, valued at $241,804. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Armando Anido bought 5,000 shares of the business’s stock in a transaction on Monday, May 15th. The shares were acquired at an average cost of $19.70 per share, for a total transaction of $98,500.00. Following the purchase, the chairman now directly owns 336,012 shares in the company, valued at $6,619,436.40. The disclosure for this purchase can be found here. Insiders own 10.02% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ZYNE. Bank of New York Mellon Corp increased its stake in shares of Zynerba Pharmaceuticals by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock valued at $245,000 after buying an additional 635 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Zynerba Pharmaceuticals during the first quarter valued at $180,000. SG Americas Securities LLC acquired a new stake in shares of Zynerba Pharmaceuticals during the first quarter valued at $188,000. Rothschild Investment Corp IL increased its stake in shares of Zynerba Pharmaceuticals by 25.1% in the second quarter. Rothschild Investment Corp IL now owns 57,070 shares of the company’s stock valued at $968,000 after buying an additional 11,450 shares during the last quarter. Finally, Cheyne Capital Management UK LLP increased its stake in shares of Zynerba Pharmaceuticals by 23.5% in the first quarter. Cheyne Capital Management UK LLP now owns 61,762 shares of the company’s stock valued at $1,241,000 after buying an additional 11,762 shares during the last quarter. 31.08% of the stock is currently owned by hedge funds and other institutional investors.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.